PURPOSE: Cross-sectional studies have established the prevalence and functional impairment of somatic symptoms in cancer patients. The purpose of this study was to determine the trajectory and adverse consequences of such symptoms over time. METHODS: Secondary analysis of longitudinal data from 405 cancer patients enrolled in a telecare management trial for pain and/or depression. Somatic symptom burden was measured with a 22-item scale at baseline, 1, 3, 6, and 12 months. Outcomes included the SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores, the Sheehan Disability Scale (SDS) score, and self-reported total disability days. Mixed methods repeated measures analyses were conducted to determine whether antecedent change in somatic symptom burden predicted functional status and disability. RESULTS: Symptoms were highly prevalent at baseline, with 15 of the 22 symptoms endorsed by more than half of the patients. A rather constant cross-sectional prevalence over 12 months at the group level belied a quite different trajectory at the patient level where the median persistence, resolution, and incidence rates for 14 of the most common symptoms were 39%, 37%, and 24%, respectively. A clinically significant (i.e., five points) reduction in somatic symptom burden predicted improvement in PCS, MCS, and SDS (all P < 0.001), as well as a lower likelihood of ≥14 disability days in the past 4 weeks (odds ratio, 0.84; 95% CI, 0.74 to 0.95). CONCLUSIONS: Somatic symptoms remain burdensome in cancer patients over 12 months and symptom improvement predicts significantly better functional status and less disability.
RCT Entities:
PURPOSE: Cross-sectional studies have established the prevalence and functional impairment of somatic symptoms in cancerpatients. The purpose of this study was to determine the trajectory and adverse consequences of such symptoms over time. METHODS: Secondary analysis of longitudinal data from 405 cancerpatients enrolled in a telecare management trial for pain and/or depression. Somatic symptom burden was measured with a 22-item scale at baseline, 1, 3, 6, and 12 months. Outcomes included the SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores, the Sheehan Disability Scale (SDS) score, and self-reported total disability days. Mixed methods repeated measures analyses were conducted to determine whether antecedent change in somatic symptom burden predicted functional status and disability. RESULTS: Symptoms were highly prevalent at baseline, with 15 of the 22 symptoms endorsed by more than half of the patients. A rather constant cross-sectional prevalence over 12 months at the group level belied a quite different trajectory at the patient level where the median persistence, resolution, and incidence rates for 14 of the most common symptoms were 39%, 37%, and 24%, respectively. A clinically significant (i.e., five points) reduction in somatic symptom burden predicted improvement in PCS, MCS, and SDS (all P < 0.001), as well as a lower likelihood of ≥14 disability days in the past 4 weeks (odds ratio, 0.84; 95% CI, 0.74 to 0.95). CONCLUSIONS: Somatic symptoms remain burdensome in cancerpatients over 12 months and symptom improvement predicts significantly better functional status and less disability.
Authors: Jürgen Unützer; Wayne Katon; Christopher M Callahan; John W Williams; Enid Hunkeler; Linda Harpole; Marc Hoffing; Richard D Della Penna; Polly Hitchcock Noël; Elizabeth H B Lin; Patricia A Areán; Mark T Hegel; Lingqi Tang; Thomas R Belin; Sabine Oishi; Christopher Langston Journal: JAMA Date: 2002-12-11 Impact factor: 56.272
Authors: Charles Given; Barbara Given; Mohammad Rahbar; Sangchoon Jeon; Ruth McCorkle; Bernadine Cimprich; Andrzej Galecki; Sharon Kozachik; Albert Brady; Mary Jo Fisher-Malloy; Kathy Courtney; Elizabeth Bowie Journal: J Clin Oncol Date: 2004-02-01 Impact factor: 44.544
Authors: Suzanne C Danhauer; Elizabeth L Addington; Lorenzo Cohen; Stephanie J Sohl; Marieke Van Puymbroeck; Natalia K Albinati; S Nicole Culos-Reed Journal: Cancer Date: 2019-04-01 Impact factor: 6.860
Authors: Kristine L Kwekkeboom; Lauren Tostrud; Erin Costanzo; Christopher L Coe; Ronald C Serlin; Sandra E Ward; Yingzi Zhang Journal: J Pain Symptom Manage Date: 2018-01-31 Impact factor: 3.612
Authors: N Fridriksdottir; S Gunnarsdottir; S Zoëga; B Ingadottir; E J G Hafsteinsdottir Journal: Support Care Cancer Date: 2017-09-18 Impact factor: 3.603
Authors: Shelley A Johns; Linda F Brown; Kathleen Beck-Coon; Patrick O Monahan; Yan Tong; Kurt Kroenke Journal: Psychooncology Date: 2014-08-17 Impact factor: 3.894
Authors: Melisa L Wong; Steven M Paul; Judy Mastick; Christine Ritchie; Michael A Steinman; Louise C Walter; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-23 Impact factor: 3.612